Skip to Content

Drug Safety and Dementia

ABCD publications

Richardson K, Fox C, Maidment I, et al. Medications with Potent Anticholinergic Activity and Incident Dementia Diagnosis in the UK Older Population. Pharmacoepidemiol Drug Saf. 2016 Aug 1;25(S3):3–679. http://onlinelibrary.wiley.com/doi/10.1002/pds.4070/full 

 

ZED publications

 

ABCD study team key publications

Gao L, Maidment I, Matthews F et alMedication usage change in older people (65+) in England over 20 years: findings from CFAS I and CFAS II Age and Ageing 2017. [Epub ahead of print]. https://academic.oup.com/ageing/advance-article/doi/10.1093/ageing/afx158/4237359

Sakel M, Boukouvalas A, Buono M et alDoes anticholinergics drug burden relate to global neuro-disability outcome measures and length of hospital stay? Brain Inj 2015;5:1-5. [Epub ahead of print]. http://informahealthcare.com/doi/abs/10.3109/02699052.2015.1060358

Richardson K, Bennett K, Maidment I, et al. Use of medications with anti-cholinergic activity and self-reported injurious falls in the older aged community-dwelling population. J Am Geriatr Soc 2015 [Epub ahead of print]. http://onlinelibrary.wiley.com/doi/10.1111/jgs.13543/abstract

Woehrling EK, Parri HR, Tse EHY, et al. A Predictive In Vitro Model of the Impact of Drugs with Anticholinergic Properties on Human Neuronal and Astrocytic Systems. PLoS ONE 2015;10:e0118786. doi:10.1371/journal.pone.0118786

Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 2014;:afu096. doi:10.1093/ageing/afu096

Peklar J, O’Halloran AM, Maidment ID, et al. Sedative Load and Frailty Among Community-Dwelling Population Aged ≥65 Years. J Am Med Dir Assoc [Epub ahead of print] doi:10.1016/j.jamda.2014.10.010

Myint PK, Fox C, Kwok CS, et al. Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population studyAge Ageing 2014;:afu185. doi:10.1093/ageing/afu185

Campbell NL, Maidment I, Fox C, et al. The 2012 Update to the Anticholinergic Cognitive Burden Scale. J Am Geriatr Soc 2013;61:S1–232. doi:10.1111/jgs.12263

Cai X, Campbell N, Khan B, et al. Long-term anticholinergic use and the aging brain. Alzheimers Dement 2013;9(4):377-85. doi:10.1016/j.jalz.2012.02.005

Fox C, Richardson K, Maidment ID, et al. Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc 2011;59:1477–83. doi:10.1111/j.1532-5415.2011.03491.x

Fox C, Livingston G, Maidment ID, et al. The impact of anticholinergic burden in Alzheimer’s Dementia-the Laser-AD study. Age Ageing 2011;40:730–5. doi:10.1093/ageing/afr102

Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 2010;75:152–9. doi:10.1212/WNL.0b013e3181e7f2ab

Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 2008;4:311–20. doi:10.2217/1745509X.4.3.311

Maidment ID. Zaleplon for Insomnia. J Pharm Technol 2001;17:39–43. doi:10.1177/875512250101700202